Connect with us

Stocks

NVAX Stock Alert: 14 Things to Know as the Novavax Vaccine Faces the FDA Today

Novavax (NVAX) is taking part in a meeting with the U.S. Food and Drug Administration (FDA) today.
This concerns an Emergency Use Authorization (EUA) for its Covid-19 vaccine.
The company is hoping that the FDA will approve its vaccine.

Sou…

  • Novavax (NVAX) is taking part in a meeting with the U.S. Food and Drug Administration (FDA) today.
  • This concerns an Emergency Use Authorization (EUA) for its Covid-19 vaccine.
  • The company is hoping that the FDA will approve its vaccine.

Source: Shutterstock

Novavax (NASDAQ:NVAX) stock is in the news today as investors prepare for results from the company’s meeting with the FDA.

Let’s go over everything investors in NVAX stock need to know about today’s meeting.

Advertisement
  • This meeting will see the FDA reviewing Novavax’s EUA application for its Covid-19 vaccine.
  • Novavax is seeking the EUA for the use of its vaccine in adults.
  • Investors will want to keep an eye out for a few things during the meeting.
  • Among these is the FDA’s response to a potential myocarditis issue with the vaccine.
  • The vaccine’s trial results include a 0.007% incident of heart inflammation.
  • This was pointed out by the FDA last week, sending shares of NVAX stock falling.
  • Another sticking point to keep in mind is the vaccine’s chemistry, manufacturing and controls (CMC) preparation.
  • 7 Cheap Growth Stocks That Won’t Stay That Way for Long
  • This is another concern the FDA has highlighted about the NVX-CoV2373 vaccine.
  • CMC is one of the main reasons the EUA meeting has been delayed for so long.
  • Another detail to note is that Novavax’s vaccine is different from other Covid-19 shots.
  • While the major focus has been on new mRNA vaccines, Novavax developed a more traditional vaccine.
  • This means it uses the same technology used for Hepatitis B and influenza vaccines.
  • Novavax could see interest in its vaccine from people that have been skeptical of mRNA alternatives.
  • Either way, investors are hoping the FDA will approve the EUA, which could be a catalyst for NVAX stock.

NVAX stock is currently halted as of this writing.

There’s more stock market news to read about below!

Advertisement

InvestorPlace has all the latest stock news for traders to dive into! This includes what’s going on with shares of GitLab (NASDAQ:GTLB), AeroClean (NASDAQ:AERC) and AIkido Pharma (NASDAQ:AIKI) today. You can catch up on that news at the following links!

More Tuesday Stock Market News

  • GitLab (GTLB) Stock Pops 20% on Q1 Earnings Beat
  • AERC Stock Is in the Spotlight After AeroClean Receives FDA Clearance
  • Why Is AIkido Pharma (AIKI) Stock Up 1,400%?

On the date of publication, William White did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.

More From InvestorPlace

  • Stock Prodigy Who Found NIO at $2… Says Buy THIS
  • It doesn’t matter if you have $500 in savings or $5 million. Do this now.
  • Get in Now on Tiny $3 ‘Forever Battery’ Stock

The post NVAX Stock Alert: 14 Things to Know as the Novavax Vaccine Faces the FDA Today appeared first on InvestorPlace.

Advertisement

InvestorPlace| InvestorPlace

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *